Back to Search
Start Over
Intravenous Immunoglobulin Protects Against Severe Pandemic Influenza Infection
- Source :
- EBioMedicine, Vol 19, Iss C, Pp 119-127 (2017), EBioMedicine
- Publication Year :
- 2017
- Publisher :
- Elsevier BV, 2017.
-
Abstract
- Influenza is a highly contagious, acute, febrile respiratory infection that can have fatal consequences particularly in individuals with chronic illnesses. Sporadic reports suggest that intravenous immunoglobulin (IVIg) may be efficacious in the influenza setting. We investigated the potential of human IVIg to ameliorate influenza infection in ferrets exposed to either the pandemic H1N1/09 virus (pH1N1) or highly pathogenic avian influenza (H5N1). IVIg administered at the time of influenza virus exposure led to a significant reduction in lung viral load following pH1N1 challenge. In the lethal H5N1 model, the majority of animals given IVIg survived challenge in a dose dependent manner. Protection was also afforded by purified F(ab′)2 but not Fc fragments derived from IVIg, supporting a specific antibody-mediated mechanism of protection. We conclude that pre-pandemic IVIg can modulate serious influenza infection-associated mortality and morbidity. IVIg could be useful prophylactically in the event of a pandemic to protect vulnerable population groups and in the critical care setting as a first stage intervention.<br />Highlights • Intravenous immunoglobulin (IVIg), prepared prior to a pandemic, prevents pandemic influenza disease in ferrets. • IVIg effectively reduced viral levels of pandemic H1N1 influenza and prevented disease due to avian influenza H5N1. • This work has implications for preventing and treating pandemic influenza infections with IVIg before a vaccine is available. Influenza pandemics cause large numbers of infections and deaths. There is a lag between the identification of a pandemic and the development of vaccines. Future pandemics may be caused by influenza strains resistant to current anti-influenza drugs. New treatments are needed for future pandemic influenza outbreaks. We show that a readily available product (intravenous immunoglobuling – pooled antibodies from human donors) can prevent viral replication and disease caused by 2 strains of pandemic influenza viruses (“swine-flu” and “bird-flu”) in an appropriate animal model of influenza. This could form the basis of future treatments for severe influenza caused by pandemic strains.
- Subjects :
- IVIg
Serum
0301 basic medicine
lcsh:Medicine
NI, neuraminidase inhibition
Antibodies, Viral
Virus Replication
medicine.disease_cause
Plasma
Influenza A Virus, H1N1 Subtype
ARRIVE, Animal Research: Reporting of In Vivo Experiments
hemic and lymphatic diseases
Pandemic
Influenza A virus
IL, Interleukin
Lung
lcsh:R5-920
biology
Immunoglobulins, Intravenous
virus diseases
Respiratory infection
General Medicine
Viral Load
IFN, Interferon
CSIRO, Commonwealth Scientific and Industrial Research Organization
Cytokines
Antibody
lcsh:Medicine (General)
Viral load
Research Paper
WHO, World Health Organization
General Biochemistry, Genetics and Molecular Biology
Virus
HI, haemagglutination inhibition
Passive immunotherapy
03 medical and health sciences
Orthomyxoviridae Infections
IVIg, intravenous immunoglobulin
medicine
Animals
Humans
RNA, Messenger
PBMC, Perpheral Blood Mononuclear Cells
Pandemics
Intravenous immunoglobulin
Influenza A Virus, H5N1 Subtype
business.industry
lcsh:R
Ferrets
HPAI, highly pathogenic avian influenza
CSL, Commonwealth Serum Laboratories
RT-PCR, Reverse Transcriptase PCR
Virology
Influenza
Influenza A virus subtype H5N1
030104 developmental biology
PBS, Phophate Buffered Saline
Immunology
biology.protein
TNF, Tumor Necrosis Factor
business
Neuraminidase
Subjects
Details
- ISSN :
- 23523964
- Volume :
- 19
- Database :
- OpenAIRE
- Journal :
- EBioMedicine
- Accession number :
- edsair.doi.dedup.....d1ab8956b302a369fe3461e7fb6a8345